Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity

Caio A. M. Tavares¹, Matthew A. Bailey² and Adriana C. C. Girardi³*

¹ Geriatric Cardiology Unit, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil, ² Centre for Cardiovascular Science, The Queen’s Medical Research Institute, The University of Edinburgh, Edinburgh, United Kingdom, ³ Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a public health crisis of major proportions. Advanced age, male gender, and the presence of comorbidities have emerged as risk factors for severe illness or death from COVID-19 in observation studies. Hypertension is one of the most common comorbidities in patients with COVID-19. Indeed, hypertension has been shown to be associated with increased risk for mortality, acute respiratory distress syndrome, need for intensive care unit admission, and disease progression in COVID-19 patients. However, up to the present time, the precise mechanisms of how hypertension may lead to the more severe manifestations of disease in patients with COVID-19 remains unknown. This review aims to present the biological plausibility linking hypertension and higher risk for COVID-19 severity. Emphasis is given to the role of the renin-angiotensin system and its inhibitors, given the crucial role that this system plays in both viral transmissibility and the pathophysiology of arterial hypertension. We also describe the importance of the immune system, which is dysregulated in hypertension and SARS-CoV-2 infection, and the potential involvement of the multifunctional enzyme dipeptidyl peptidase 4 (DPP4), that, in addition to the angiotensin-converting enzyme 2 (ACE2), may contribute to the SARS-CoV-2 entrance into target cells. The role of hemodynamic changes in hypertension that might aggravate myocardial injury in the setting of COVID-19, including endothelial dysfunction, arterial stiffness, and left ventricle hypertrophy, are also discussed.

INTRODUCTION

The severe acute respiratory coronavirus 2 (SARS-CoV-2) infection, named coronavirus disease 2019 (COVID-19), was initially described as a series of cases of atypical pneumonia arising in Wuhan, China, in December 2019 (Zhu et al., 2020). The rapid spread of COVID-19 in many countries worldwide has given rise to a global public health crisis of unprecedented proportions in the modern era. As of October 9, 2020, the SARS-CoV-2 has infected 36,669,238 individuals, with 1,063,863 deaths globally (Dong et al., 2020).
The clinical spectrum of COVID-19 ranges from asymptomatic infection to mild or moderate respiratory and associated symptoms (cough, sore throat, nasal congestion, myalgia, arthralgia, headache, shortness of breath) (Guan et al., 2020b) to severe pneumonia accompanied by multiorgan failure which may result in death. Accumulated evidence from the first months of the COVID-19 pandemic has also linked several risk factors with the development of severe morbidity and mortality, such as advanced age, male gender, and the coexistence of underlying chronic diseases. Indeed, the presence of comorbidities, especially hypertension, have been consistently reported as more common among patients with COVID-19 in severe conditions, admitted to the intensive care unit (ICI), who received mechanical ventilation or died, than among patients with mild symptoms (Guan et al., 2020b; Wang et al., 2020; Wu et al., 2020; Zhou et al., 2020a).

Hypertension represents one of the most prevalent comorbidities in patients with COVID-19. Since the first observational data available from China, in early March, hypertension has emerged as a potential risk factor for COVID-19 severity and mortality in different cohorts (Guan et al., 2020b; Zhang et al., 2020; Zhou et al., 2020a). With the pandemic progression worldwide, the association of hypertension and unfavorable outcomes was also seen in other countries such as Italy (Grasselli et al., 2020; Mancia et al., 2020) and the United States (Garg et al., 2020). However, at present, the precise impact of hypertension per se on COVID-19 severity is yet to be defined. This review aims to present the biological plausibility linking hypertension and higher risk for COVID-19 severity. To this end, we discuss how cellular, molecular, and functional alterations that underlie the pathophysiology of hypertension can impact the severity of the SARS-CoV-2 infection, thereby predisposing hypertensive patients to more complicated clinical outcomes.

**ROLE OF THE RENIN-ANGIOTENSIN SYSTEM (RAS)**

The RAS is a key player both in the SARS-CoV-2 transmissibility and in the pathophysiology of hypertension. It consists of a complex network of precursors, enzymes, effector peptides, and receptors that exerts a vital role in blood pressure control, extracellular volume homeostasis, and cardiac function, among several other physiological processes. Abnormal activation of RAS components, ultimately leading to the upregulation of angiotensin II (Ang II) and activation of its angiotensin II type 1 receptor (AT1R), contribute to the development and progression of hypertension (Carson et al., 2001; Dahlof et al., 2002; Crowley et al., 2005, 2006; Gurley et al., 2011).

Angiotensin-converting enzyme 2 (ACE2), a type I integral membrane protein, is a homolog of angiotensin-converting enzyme (ACE), the central enzyme of classical RAS (Tipnis et al., 2000). ACE2 is expressed in organs that are important for blood pressure control such as kidneys, vessels, brain, and heart, where it hydrolyzes Ang II (Donoghue et al., 2000; Tipnis et al., 2000). ACE2 is also found in the lungs, small intestine, ovaries, and testicles (Tipnis et al., 2000). Additionally, ACE2 has been identified as a functional receptor for the SARS-CoV-2 host cell entry (Hoffmann et al., 2020) as well as for its predecessor SARS-CoV (Kuba et al., 2005). Binding of the viral spike (S) protein of the SARS-CoV-2 to the extracellular domain of ACE2 triggers conformational changes that destabilize the membrane allowing the internalization of the SARS-CoV-2 along with ACE2, leading to ACE2 cell surface expression downregulation, viral replication and cell-to-cell transmission (Heurich et al., 2014; Hoffmann et al., 2020). During this process, the cleavage of the S protein by host cell proteases, including the transmembrane serine protease 2 (TMPRSS2), is essential for viral infectivity (Iwata-Yoshikawa et al., 2019). As such, TMPRSS2 constitutes a potential target for the treatment of SARS-CoV-2 infected patients.

As a bioactive component of the RAS, ACE2 functions as a counterregulatory enzyme, converting Ang II to Ang-(1-7). This heptapeptide binds to the Mas receptor (MasR), modestly reducing blood pressure, promoting vasodilation, increasing excretion of sodium and water by the kidneys, and exerting anti-inflammatory and antioxidative effects (Santos et al., 2018). These actions are directly opposed to those induced by the activation of the ACE/Ang II/AT1R axis. ACE converts Ang I to Ang II, which in turn acts on the AT1R, increasing blood pressure, inducing vasoconstriction, increasing renal tubular salt and water reabsorption, and increasing the production of reactive oxygen species (ROS) that promote inflammation and fibrosis (Benigni et al., 2010). The ACE/Ang II/AT1R and ACE2/Ang-(1-7)/MasR pathways are co-expressed in most tissues and act in an autocrine and paracrine manner. Thus, the balance between these pathways determines, at least in part, whether or not tissue damage will occur in response to pathological stimuli.

The kidney is a target for end-organ damage in hypertension, plays an active role in the pathogenesis of hypertension, and it is one of the sites of the highest levels of expression of ACE2 (Gembardt et al., 2005). Several studies have found that the protein and mRNA abundance, as well as the activity of ACE2, are reduced in the kidneys of experimental models of hypertension, including spontaneously hypertensive rats, renin transgenic hypertensive rats, aldosterone/NaCl-induced hypertension and the model of 2 kidneys 1 clip (2K1C) hypertensive rats (Soler et al., 2013). In mice on the C57BL/6 genetic background, (Gurley et al., 2006) have found that ACE2 deficiency was associated with a significant increase in blood pressure of ~7 mmHg and that the absence of ACE2 considerably enhanced the severity of Ang II-dependent hypertension. Moreover, ACE2-deficient mice chronically treated with Ang II infusion displayed a more than 5-fold higher renal Ang II concentration than Ang II-treated wild-type animals, thereby suggesting that the more severe hypertension in ACE2-deficient mice may be attributed to an impaired metabolism of Ang II in the kidney (Gurley et al., 2006). Notably, Ang II upregulates ACE and downregulates ACE2 expression in human proximal tubule cells via an AT1R-mediated mechanism (Koka et al., 2008), thereby suggesting that ACE and ACE2 may be regulated in a balanced manner, which can be mediated via the local Ang II concentration. This synergistic regulation is observed in renal biopsies from humans, in which the ACE to ACE2 ratio is significantly higher in
subjects with hypertension than in subjects without hypertension (Wakahara et al., 2007). The human kidney is a target for the SARS-CoV-2 infection (Braun et al., 2020; Puelles et al., 2020). Acute kidney injury (AKI) has been observed in COVID-19 patients, and it is considered a marker of COVID-19 severity and an adverse prognostic factor for survival (Cheng et al., 2020). Renal Ang II overactivity in the setting of hypertension and potentiated by SARS-CoV-2 induced ACE2 internalization, may contribute to the pathogenesis of AKI in severely ill patients with COVID-19. Favoring this hypothesis are the findings of a prospective cohort study of 701 patients with COVID-19 conducted by Cheng et al. (2020). These authors investigated the association between inpatient use of medications and the development of AKI among patients with COVID-19. It was observed that none of the patients who were taking RAS inhibitors on admission or during hospitalization for COVID-19 developed AKI (Guan et al., 2020a).

Angiotensin-converting enzyme 2 expression is relatively abundant in the heart, where it can be found in cardiomyocytes, endothelial cells, and fibroblasts (Santos et al., 2018). Crackower et al. (2002) have found that ACE2 knockout mice display increased heart content of Ang II and cardiac dysfunction characterized by a decrease in fractional shortening with slight ventricular dilation. Moreover, these authors have observed that cardiac dysfunction of ACE2 knockout mice progressed with age, and it was more pronounced in males than in females. The fact that cardiac phenotype and increased Ang II levels were completely reversible by deleting the ACE gene in ACE2 knockout mice strengthens the notion that cardiac function is modulated by the balance between ACE and ACE2, and that the increase in local cardiac Ang II was involved in cardiac impairment (Crackower et al., 2002). The cardiac effects of ACE2 remain under debate since ACE2 deletion mediated-cardiac dysfunction was not observed by Gurley and colleagues. On the other hand, it is well accepted that increased cardiac Ang II, generated by cardiac ACE, drives left ventricular hypertrophy (LVH) in multiple settings, including hypertension (Sadoshima and Izumo, 1993; Crowley et al., 2006; Ainscough et al., 2009). Therefore, patients with hypertension are particularly susceptible to the imbalance between the ACE/Ang II/AT1R, and ACE2/Ang-(1-7)/MasR, further intensified by myocardial SARS-CoV-2-mediated ACE2 internalization (Huentelman et al., 2005). Indeed, loss of surface ACE2 in cardiac cells may be one of the underlying causes of acute, and perhaps long-term, exacerbation of cardiovascular disease in hypertensive patients infected with SARS-CoV-2.

Extrapolating data from SARS-CoV to SARS-CoV-2, one may postulate that the imbalance in the signaling and actions of products of ACE/ACE2, generated by the loss of ACE2 cell surface expression due to SARS-CoV-2 infection, may lead to severe acute respiratory failure in COVID-19 (Kuba et al., 2005). The existence of a causal relationship between the imbalanced ACE/ACE2 axis and the acute respiratory distress syndrome has been established through the use of genetically modified animals (Imai et al., 2005; Kuba et al., 2005). Imai et al. (2005) have found that acute lung injury induced by acid aspiration results in decreased expression of ACE2 and increased lung content of Ang II in wild-type mice. Additionally, ACE2 knockout mice with severe acute lung injury induced by acid aspiration or sepsis displayed a higher rate of mortality and lung failure than wild type mice with severe acute lung injury (Imai et al., 2005). Conversely, the genetic deletion of ACE in ACE2 knockout mice significantly attenuated these outcomes, demonstrating that ACE/Ang II drive severe lung, whereas ACE2 protects against it. The levels of ACE2 gene expression appear to be upregulated in the lung of patients with pulmonary hypertension when compared to controls (Pinto et al., 2020), however, to our knowledge, the modulation of lung ACE to ACE2 ratio in essential arterial hypertension remains elusive.

ROLE OF RAS INHIBITORS

During the early beginning of the COVID-19 pandemic, concerns emerged that RAS inhibitors, cornerstone treatment of several cardiovascular diseases, including hypertension, could promote viral interaction with host cells, leading to increased cell entry, viral replication and thereby COVID-19 exacerbation (Diaz, 2020; Esler and Esler, 2020). These concerns were primarily based on findings that ACE inhibitors (ACEI) or angiotensin II type 1 receptor (ARB) upregulate the expression and activity of ACE2, the SARS-CoV-2 receptor, in the kidneys and heart of experimental models of hypertension (Ferrario et al., 2005; Jessup and Izumo, 1993; Crowley et al., 2006; Ainscough et al., 2009).

As the pandemic evolved, several observational studies indicated that ACEi/ARBs use are not a risk factor for disease severity and may actually be related to milder disease and better outcomes ( Supplementary Table S1) possibly by attenuating the imbalance between ACE/Ang II/AT1R and ACE2/Ang-(1-7)/MasR, reducing pathogenic inflammation and multiorgan injury. Also, evidence from population studies suggests that RAS inhibitors neither increase the risk of SARS-CoV-2 infection in patients with hypertension nor negatively impact the disease severity in those who are infected, establishing its safety and reinforcing that they should not be switched/stopped during the pandemic (Mancia et al., 2020; Mehta et al., 2020; Reynolds et al., 2020).

Ongoing clinical trials will add crucial information on the impact of RAS on COVID-19 severity. Currently, several studies are registered in the clinicaltrials.gov platform aiming to investigate the effects of ACEi/ARBs replacement or withdrawn on patients with COVID-19 ( Table 1), the impact of ACEi/ARBs initiation in patients without hypertension on the risk of COVID-19 infection and severity ( Table 2) and whether modulation of RAS by other agents with antihypertensive actions [AT1R biased agonist, Ang-(1-7) analogs, DPP4 inhibitors or recombinant ACE2] can impact COVID-19 outcomes ( Table 3).

INFLAMMATION

There is strong evidence from human and experimental studies to show that chronic hypertension accrues sustained, low-grade inflammation, stimulating the adaptive immune
TABLE 1

<table>
<thead>
<tr>
<th>Category</th>
<th>NCT number</th>
<th>Study design</th>
<th>Acronym</th>
<th>Intervention arm</th>
<th>Study population</th>
<th>Target enrollment</th>
<th>Primary outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEi</td>
<td>NCT04330300</td>
<td>Randomized, open-label</td>
<td>CORONACION</td>
<td>Switch RAAS inhibitor to alternative medication</td>
<td>Ambulatory hypertensive patients without COVID-19</td>
<td>214</td>
<td>Composite: death, mechanical ventilation, ICU hospitalization, or hospitalization for NIV</td>
</tr>
<tr>
<td>ARB</td>
<td>NCT04351581</td>
<td>Randomized, single-blind</td>
<td>RASCOVID-19</td>
<td>Discontinue RAAS inhibitor and start other medication</td>
<td>Hospitalized patients with COVID-19 and use of RAAS inhibitors</td>
<td>215</td>
<td>Composite: death and days out of hospital within 14 days of recruitment</td>
</tr>
<tr>
<td>ACEi</td>
<td>NCT04353596</td>
<td>Randomized, single-blind</td>
<td>ACEI-COVID</td>
<td>Stoping or replacing ACEi/ARB for 30 days</td>
<td>COVID-19 infection</td>
<td>208</td>
<td>SOFA/Death ≤ 5 days, ICU/MV/Death</td>
</tr>
<tr>
<td>ACEi</td>
<td>NCT04364893</td>
<td>Randomized, open-label</td>
<td>BRACE-CORONA</td>
<td>Temporarily discontinuation of ACEi/ARB for 30 days</td>
<td>Hospitalized patients with COVID-19</td>
<td>700</td>
<td>Time to clinical improvement on a seven-category ordinal scale from the clinician-given protocol</td>
</tr>
<tr>
<td>ACEi</td>
<td>NCT04329195</td>
<td>Randomized, open-label</td>
<td>ACORES-2</td>
<td>Discontinuation of RAS blockers</td>
<td>Hospitalized patients with COVID-19</td>
<td>554</td>
<td>Time to clinical improvement on a seven-category ordinal scale from the clinician-given protocol</td>
</tr>
<tr>
<td>ACEi</td>
<td>NCT04338009</td>
<td>Randomized, single-blind</td>
<td>REPLACECOVID</td>
<td>Discontinuation of ACEi/ARB</td>
<td>Hospitalized patients with COVID-19</td>
<td>152</td>
<td>Hierarchical/Composite: (1) time to death; (2) days supported by RRT; (3) days supported by ECMO/VAD</td>
</tr>
</tbody>
</table>

By blood pressure ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; MV, mechanical ventilation; RFT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment; VAD, ventricular assist device.
### Table 2 | Ongoing randomized trials comparing ACEi/ARBs initiation to mitigate COVID-19 severity in patients with COVID-19.

<table>
<thead>
<tr>
<th>Category</th>
<th>NCT number</th>
<th>Study design</th>
<th>Acronym</th>
<th>Intervention arm</th>
<th>Study population</th>
<th>Target enrollment</th>
<th>Primary outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04345406</td>
<td>Randomized, open-label</td>
<td>N/A</td>
<td>ACE inhibitors</td>
<td>Patients with COVID-19 without contra-indication to ACE inhibitors</td>
<td>60</td>
<td>Number of patients with virological cure</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04366050</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>RAMIC</td>
<td>Ramipril 2.5 mg for 14 days</td>
<td>Hospitalized patients or in a emergency department with COVID-19</td>
<td>560</td>
<td>Composite: death, need for ICU admission or MV</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04355429</td>
<td>Randomized, open-label</td>
<td>CAPTOCOVID</td>
<td>Captopril 25 mg by nebulization</td>
<td>Hospitalized patients with COVID-19 needing oxygen</td>
<td>230</td>
<td>Ventilator free survival at 14 days</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04360551</td>
<td>Randomized, double-blind, placebo controlled</td>
<td>N/A</td>
<td>Telmisartan 40 mg</td>
<td>Outpatients with COVID-19</td>
<td>40</td>
<td>Maximal clinical severity on a seven-category ordinal scale</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04335786</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>PRAETORIAN-COVID</td>
<td>Valsartan 80 to 160 mg titrated by blood pressure</td>
<td>Hospitalized patients with COVID-19</td>
<td>651</td>
<td>Composite: death, mechanical ventilation or ICU admission</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04394117</td>
<td>Randomized, single-blind (outcomes assessor)</td>
<td>CLARITY</td>
<td>Initiation of an ARB or switching from non-RAAS inhibitor to ARB</td>
<td>Confirmed COVID-9</td>
<td>605</td>
<td>Improvement on a seven-category ordinal scale</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04340557</td>
<td>Randomized, open-label</td>
<td>N/A</td>
<td>Losartan 12.5 mg up titrated according to BP</td>
<td>Hospitalized patients with COVID-19 and mild to moderate hypoxia</td>
<td>200</td>
<td>Need for MV</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04312009</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>N/A</td>
<td>Losartan 50 mg daily</td>
<td>Hospitalized patients with COVID-19 requiring oxygen therapy</td>
<td>200</td>
<td>The difference in P/F ratio at 7 days</td>
</tr>
<tr>
<td>ACEi or ARB initiation</td>
<td>NCT04343001</td>
<td>Randomized, factorial design (2 × 2 × 2), open-label</td>
<td>CRASH-19</td>
<td>Losartan 100 mg daily Other interventions: Aspirin, Simvastatin</td>
<td>Hospitalized patients with COVID-19</td>
<td>10000</td>
<td>Mortality up to 28 days</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Category</th>
<th>NCT number</th>
<th>Study design</th>
<th>Acronym</th>
<th>Intervention arm</th>
<th>Study population</th>
<th>Target enrollment</th>
<th>Primary outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04328012</td>
<td>Randomized, double-blind, placebo-controlled, 4 groups (parallel)</td>
<td>COVIDMED</td>
<td>Losartan 25 mg daily Other interventions: Lopinavir/Ritonavir, Hydroxychloroquine</td>
<td>Hospitalized patients with COVID-19</td>
<td>4000</td>
<td>The difference in the ordinal scale of disease severity</td>
<td></td>
</tr>
<tr>
<td>NCT04359953</td>
<td>Randomized, open-label, 4 groups (parallel)</td>
<td>COVID-Aging</td>
<td>Telmisartan 40 mg twice daily Other interventions: Azithromycin, Hydroxychloroquine</td>
<td>Hospitalized patients with COVID-19 and age $\geq$ 75 years or $\geq$ 60 years if dementia</td>
<td>1600</td>
<td>Mortality up to 14 days</td>
<td></td>
</tr>
<tr>
<td>NCT04351724</td>
<td>Randomized, open-label, adaptative trial</td>
<td>ACOVACT</td>
<td>RAS Blockade substudy Candesartan 4 mg daily, uptitrated Other interventions: Chloroquine, Lopinavir/Ritonavir, Rivaroxaban and Clazakizumab</td>
<td>Hospitalized patients with COVID-19 and blood pressure $\geq$120/80 mmHg</td>
<td>500</td>
<td>Sustained clinical improvement on a seven-category ordinal scale</td>
<td></td>
</tr>
<tr>
<td>NCT04356495</td>
<td>Randomized, open-label, multi-arm multi-stage trial</td>
<td>COVERAGE</td>
<td>Telmisartan 20 mg daily Other interventions: Hydroxychloroquine, Imatinib, and Faviparavir</td>
<td>Outpatients with COVID-19</td>
<td>1057</td>
<td>Primary outcomes: 1- Mortality up to 14 days 2- Need for hospitalization up to 14 days</td>
<td></td>
</tr>
<tr>
<td>NCT04447235</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>TITAN</td>
<td>Ivermectin plus Losartan 50 mg daily</td>
<td>Cancer patients with COVID-19</td>
<td>176</td>
<td>Composite: mortality, need for MV or ICU admission up to 28 days</td>
<td></td>
</tr>
<tr>
<td>NCT04311177</td>
<td>Randomized, double-blind, placebo controlled</td>
<td>N/A</td>
<td>Losartan 25 mg</td>
<td>Symptomatic COVID-19 infection</td>
<td>516</td>
<td>Hospital admission up to 15 days</td>
<td></td>
</tr>
<tr>
<td>NCT04355936</td>
<td>Randomized, open-label</td>
<td>N/A</td>
<td>Telmisartan 80 mg twice daily</td>
<td>COVID-19 infection</td>
<td>400</td>
<td>CRP at days 1.8 and 15</td>
<td></td>
</tr>
<tr>
<td>NCT04428268</td>
<td>Randomized, double-blind</td>
<td>N/A</td>
<td>Losartan 25 mg twice daily Chloroquine vs. Chloroquine/Losartan</td>
<td>Hospitalized patients with COVID-19</td>
<td>20</td>
<td>Mortality up to 28 days</td>
<td></td>
</tr>
</tbody>
</table>
# TABLE 3

Ongoing clinical trials testing the hypothesis that modulation of RAS components can impact COVID-19 severity.

<table>
<thead>
<tr>
<th>Category</th>
<th>NCT number</th>
<th>Study design</th>
<th>Acronym</th>
<th>Intervention arm</th>
<th>Study population</th>
<th>Target enrollment</th>
<th>Primary outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant ACE2</td>
<td>NCT04382950</td>
<td>Randomized, open-label</td>
<td>N/A</td>
<td>Recombinant ACE2 infusion plus aerosolized isotretinoin</td>
<td>Hospitalized patients with COVID-19 and respiratory failure</td>
<td>24</td>
<td>Fever</td>
</tr>
<tr>
<td>NCT04375046</td>
<td></td>
<td>Randomized, open-label</td>
<td>Bacterial ACE2</td>
<td>Recombinant ACE2 infusion</td>
<td>Hospitalized patients with COVID-19</td>
<td>24</td>
<td>(1) Fever</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2) Viral load</td>
</tr>
<tr>
<td>NCT04335136</td>
<td></td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>APN01-COVID-19</td>
<td>Recombinant ACE2 infusion</td>
<td>Hospitalized patients with COVID-19</td>
<td>200</td>
<td>Composite: death or mechanical ventilation up to 28 days or hospital discharge</td>
</tr>
<tr>
<td>Biased agonist of AT1R</td>
<td>NCT04419610</td>
<td>Randomized, double-blind, placebo-controlled</td>
<td>N/A</td>
<td>TRV027 at 12 mg/hour until discharge or 7 days</td>
<td>Hospitalized patients with COVID-19</td>
<td>60</td>
<td>Mean change from baseline D-dimer at day 8</td>
</tr>
<tr>
<td>Ang 1-7 analogs</td>
<td>NCT04332666</td>
<td>Randomized, double-blind, placebo controlled</td>
<td>ATCO</td>
<td>Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h</td>
<td>Hospitalized patients with COVID-19 and MV</td>
<td>60</td>
<td>Composite: mortality and MV-free days</td>
</tr>
<tr>
<td></td>
<td>NCT04375124</td>
<td>Non-randomized, open label</td>
<td>N/A</td>
<td>Angiotensin peptide (1-7) derived plasma</td>
<td>Hospitalized patients with COVID-19</td>
<td>20</td>
<td>Mortality up to 4 months</td>
</tr>
<tr>
<td>DPP4 inhibitors</td>
<td>NCT04341935</td>
<td>Randomized, open-label</td>
<td>N/A</td>
<td>Linagliptin 5 mg daily</td>
<td>Hospitalized patients with COVID-19</td>
<td>100</td>
<td>1-Acute kidney injury up to 7 days</td>
</tr>
<tr>
<td></td>
<td>NCT04371978</td>
<td>Randomized, open-label</td>
<td>N/A</td>
<td>Linagliptin 5 mg daily</td>
<td>Hospitalized patients with COVID-19</td>
<td>20</td>
<td>2-Need for VM up to 7 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Changes in glucose levels</td>
</tr>
</tbody>
</table>

Ang-1-7, Angiotensin-1-7; AT1R, Angiotensin II type 1 Receptor; DPP4, Dipeptidyl peptidase 4.
local inflammation since ACE2 converts pro-inflammatory Ang II to Ang-(1-7), which has anti-inflammatory roles. It is evident that the inflammation response to COVID-19 is amplified in hypertensives compared to normotensive controls (Yang et al., 2020). In humans, high levels of systemic inflammation driven by infection induce a short-lived, extensive endothelial dysfunction (Hingorani et al., 2000) that would be anticipated to transiently increase cardiovascular risk. It is not difficult to imagine that this risk would be exaggerated for individuals with a vulnerable cardiovascular system, such as those with hypertension. Of importance, in patients receiving antihypertensive medicines, those on ACEi or ARBs had reduced levels of inflammatory biomarkers (C-reactive protein and procalcitonin) and better outcomes than those on other antihypertensive medication (Yang et al., 2020). These outcomes from a retrospective, single-center cohort (Wuhan, China) study give some insight suggesting that immune system/blood pressure interactions are important for COVID-19 severity, and also that ACEi, may have beneficial cardiovascular effects in this setting beyond blood pressure control. Indeed, targeting excessive inflammation is an attractive strategy to improve the health of the arterial cardiovascular system (Zanoli et al., 2020) and may be particularly relevant in understanding cardiovascular risk in COVID-19.

HEMODYNAMIC FACTORS

Endothelial Dysfunction

Endothelial cells play a vital role in cardiovascular homeostasis by controlling vasomotor tone, maintaining vascular integrity, exerting barrier protecting effects, and preventing platelet and leukocyte adhesion and aggregation (Deanfield et al., 2007). It also regulates fibrinolysis and the coagulation cascade, provides antiproliferative and anti-inflammatory actions, and protects against oxidative stress (Deanfield et al., 2007). In turn, abnormalities of the vascular endothelium significantly contribute to a plethora of cardiovascular disorders.

A large body of evidence demonstrates the presence of endothelial dysfunction in patients with hypertension (Watson et al., 2008). Endothelial dysfunction is characterized by imbalanced vasodilation and vasoconstriction, elevated ROS and pro-inflammatory mediators, as well as reduced bioavailability of nitric oxide (NO) (Deanfield et al., 2007; Watson et al., 2008).

As aforementioned, Ang II, via AT1R, is a potent activator of oxidative and inflammatory cascades, the primary mediators of endothelial dysfunction. Under physiological conditions, however, the ACE2/Ang-(1-7)/MasR axis stimulates the activity of the endothelial NO synthase, increasing NO production. Adding up to this effect, Ang-(1-7) decreases the activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase stimulated by Ang II, directly modulating the generation of reactive ROS (Sampaio et al., 2007).

Many severe COVID-19 patients show signs of a cytokine storm that could be aggravated due to overactivation of Ang II, increased production of ROS, and a preexistent pro-inflammatory state, features of hypertension associated-chronic endothelial dysfunction. In fact, endothelitis and an increase in D-dimer (a marker of activation of coagulation and fibrinolysis) have been described in the pathological findings of patients with COVID-19 (Tang et al., 2020; Varga et al., 2020). Therefore, it is plausible to postulate that circulating SARS-CoV-2 may interact with endothelial cells of hypertensive patients culminating both in direct viral injury and in a dysfunctional response to infection, amplifying chemokine release, inflammatory cell adhesion and migration through the endothelial barrier, ultimately leading to a procoagulant state and tissue damage (i.e., myocardial injury, acute respiratory distress syndrome) (Ackermann et al., 2020; Bermejo-Martin et al., 2020).

Arterial Stiffness

Arterial stiffness describes the reduced capability of an artery to expand and contract in response to pressure changes. It is measured by carotid-femoral pulse wave velocity and is an independent predictor of cardiovascular (CV) events and mortality in patients with hypertension (Laurent et al., 2001).

Potentially, high arterial stiffness could have deleterious effects in patients with SARS-CoV-2 infection thorough different putative mechanisms: (i) chronically, arterial stiffness can increase the energy penetration of the increased pulsatile flow from the larger arteries, damaging target organs (brain, kidney, heart) and aggravating the infection by mitigating the functional reserves of different systems; (ii) the COVID-19 cytokine-storm may cause ventricular-arterial decoupling in the setting of low systemic vascular resistance and elevated heart rate. In this scenario, patients with high arterial stiffness could be more prone to ventricular-arterial decoupling by increasing pulsatile components of the total arterial load to the left ventricle (LV): proximal aortic impedance, wave reflections and arterial tree compliance (Chirinos et al., 2014, 2019; Ikonomidis et al., 2019) which ultimately leads to increased myocardial oxygen demand, CV inefficiency, and left ventricle (LV) energetic failure (Chemla et al., 2003; Guarracino et al., 2014); and (iii) increased arterial stiffness is associated with reduced coronary flow reserve in hypertensive patients (Ikonomidis et al., 2008) and lower diastolic blood pressure (coronary perfusion pressure), rendering these patients more vulnerable to myocardial injury and ischemia - a known complication of COVID-19 (Hendren et al., 2020).

Another intriguing aspect warranting exploration is whether survivors of COVID-19 will develop long term vascular sequelae of the infection, such as increased arterial stiffness and accelerated vascular aging. The Artery Society recently launched a collaborative, multicenter, research project to evaluate the vascular impact of the infection1 and will periodically test different biomarkers of aging in patients that had COVID-19.

Left Ventricle Hypertrophy

Prolonged systemic hypertension results in hypertensive target-organ damage, and the most common manifestation of this is left ventricular hypertrophy (LVH). LVH - due to cellular hypertrophy and expansion of extracellular matrix - is defined as an increase in the mass of the left ventricle secondary to chronically elevated afterload and neurohormonal stimuli

1http://www.arterysociety.org/our-activities/cartesian-2/
LVH can indeed be the cause of poorer outcomes in patients with disturbances. This overlap of hemodynamics and electrical aggravating factors such as mechanical ventilation, vasoactive ventricular arrhythmias and sudden cardiac death (Aro and patients might be related to an increased risk of malignant in LV relaxation (Chin et al., 2013; Juhl-Olsen et al., 2013). That can occur after weaning of the initial compensatory mechanism due to contractile, electrical, structural or metabolic abnormalities (Pitolis and Terracciano, 2020).

Myocardial injury among patients hospitalized with COVID-19 has been described since the early reports of the disease (Zhou et al., 2020a). Although being an important prognostic factor in severe cohorts (Guo et al., 2020; Lala et al., 2020; Shi et al., 2020a,b), the exact mechanism of myocardial injury is not fully understood as multiple plausible mechanisms often coexist in a single patient including multiorgan failure, types 1 and 2 myocardial infarction, disseminated intravascular coagulation, endothelial cell dysfunction, pre-existing chronic injury, pulmonary hypertension, among others (Jaffe et al., 2020). It is also unknown if there is a causal relationship between myocardial injury and disease severity or if it is solely a marker of pre-existing cardiovascular disease. LVH-related changes in the myocardial tissue and extracellular matrix might be related to both an increased risk of myocardial injury due to several pathophysiological pathways (increased cardiac Ang II, endothelial dysfunction, chronic inflammation, upregulated cardiac DPP4 expression) and an abolished cardiovascular response to the stress related to the infection.

Left ventricular hypertrophy imposed changes of cardiac structure function can complicate further the management of these patients in the intensive care unit (ICU), as LV compliance and diastolic function are impaired: the rise in the end-diastolic pressure narrows the optimal volume status for hemodynamics stability without pulmonary congestion (Sanfilippo et al., 2018); sinus tachycardia or supraventricular arrhythmias with rapid ventricular response can trigger hemodynamic collapse by reduced LV filling time-related to increase in the heart rate (Borlaug et al., 2011); increased LV filling pressure is also an independent risk factor for weaning failure from mechanical ventilation (Papanikolaou et al., 2011; Konomi et al., 2016; Liu et al., 2016) and the use high positive end-expiratory pressure during mechanical ventilation can lead to additional impairment in LV relaxation (Chin et al., 2013; Juul-Olsen et al., 2013).

Also, the electrical remodeling due to LVH in hypertensive patients might be related to an increased risk of malignant ventricular arrhythmias and sudden cardiac death (Aro and Chugh, 2016), as they are being treated in the ICU with other aggravating factors such as mechanical ventilation, vasoactive drugs, medications that prolong the QT interval, and electrolyte disturbances. This overlap of hemodynamics and electrical disorders reflecting cellular and molecular remodeling due to LVH can indeed be the cause of poorer outcomes in patients with COVID-19 being treated in the ICU and poises a great challenge for clinicians that need to untangle the complexity of a serious illness aggravated by pre-existing conditions.

ROLE OF DIPEPTIDYL PEPTIDASE 4 (DPP4)

Bioinformatic approaches based on protein structure predicted that the middle east respiratory syndrome coronavirus (MERS-CoV) receptor DPP4 displays a high affinity with the SARS-CoV-2 spike protein (Li et al., 2020). This thereby suggests that SARS-CoV-2 may utilize DPP4 as a coreceptor, in addition to ACE2, to gain entry into the host cell. Nevertheless, the results of free energy calculation revealed that SARS-CoV-2 spike protein binds ACE2 with higher affinity than that of DPP4 (Li et al., 2020). Moreover, it was shown that only Hela and baby kidney hamster (BHK2) cells transfected with human ACE2, but not with human DPP4, were capable of being infected with SARS-CoV-2 (Hoffmann et al., 2020; Letko et al., 2020; Zhou et al., 2020b). However, further research is necessary to defined whether or not DPP4 may mediate the SARS-CoV-2 entry into permissive cells.

Dipeptidyl peptidase is a serine peptidase expressed on the surface of several cell types, including epithelial and endothelial cells and lymphocytes (Kenny et al., 1976; Marguet et al., 2000; Lambeir et al., 2003). It also exists as a soluble circulating form in plasma and other body fluids (Lambeir et al., 2003). Through its enzymatic function, DPP4 modulates the biological activity of several circulating hormones, neuropeptides, cytokines, and chemokines. In addition to its peptidase, activity DPP4 interacts with several proteins, including the renal proximal tubule Na+/H+ exchanger isoform 3 (NHE3) (Girardi et al., 2001), fibronectin and collagen, adenosine deaminase (ADA), C-X-C chemokine receptor type 4, underscoring the potential role of DPP4 in sodium retention, fibrosis, and inflammation. The importance of DPP4 for the scientific and medical community has considerably raised since the approval of inhibitors of DPP4 activity, known as gliptins, for the treatment of type 2 diabetes (T2D).

The gliptins do not bind to the putative receptor binding site of SARS-CoV-2 (Li et al., 2020). However, it does not exclude the possibility that DPP4 inhibition may indirectly attenuate the severity of COVID-19, due to the role that DPP4 plays in the pathophysiology of common comorbidities in patients with COVID-19 (Ryskjaer et al., 2006; Dos Santos et al., 2013; Zhong et al., 2013), including hypertension. Indeed, successive clinical studies have demonstrated that gliptins confer renal and cardiovascular benefits in patients with hypertension with or without T2D (Nistala and Savin, 2017). Intriguingly, although known primarily for its role as competitive inhibitors, gliptins are also capable of reducing DPP4 protein and mRNA abundance in the heart, kidneys, and endothelial cells of experimental animals of cardiovascular and metabolic diseases (Dos Santos et al., 2013; Kanasaki et al., 2014; Arruda-Junior et al., 2016; Beraldo et al., 2019). Whether altered DPP4 expression in the setting of hypertension, as well as of other comorbidities,
contributes to SARS-CoV-2 infectivity, and COVID-19 severity is currently undetermined.

Recent evidence suggests the existence of an interplay between DPP4 and tissue RAS (Aroor et al., 2016; Beraldo et al., 2019). In renal proximal tubule cells, Ang II, through AT1R, enhances DPP4 activity, whereas inhibition of DPP4 mitigates Ang II-mediated activation of AT1R signaling and its downstream effects (Aroor et al., 2016). In rats with chronic kidney disease (CKD) and hypertension, the administration of the DPP4 inhibitor sitagliptin ameliorated hypertension, kidney function and restored the cardiac ratio of Ang II to Ang-(1-7) concentrations in the heart by reducing the levels of Ang II and increasing the content of Ang-(1-7) (Beraldo et al., 2019). Interestingly, sitagliptin was capable of upregulating ACE2 expression in the heart of rats with CKD and as well as in control animals (Beraldo et al., 2019). In line with these findings, Zhang et al. (2015) found that the DPP4 inhibitor linagliptin lowered the expression of the AT1R and upregulated the activity of ACE2 in the heart in rats with Ang II-induced hypertension. Collectively, these studies support the hypothesis that increased DPP4 activity and expression can favor an imbalance between ACE/Ang II/AT1R and ACE2/Ang-(1-7)/MasR.

The vascular activity and expression of DPP4 are increased in hypertensive rats (Linardi et al., 2004; Savignano et al., 2017), suggesting that this peptidase may contribute to impaired vascular function associated with high blood pressure. Accordingly, extensive studies have shown that DPP4 inhibitors play a protective effect against hypertension-related vascular events, such as endothelial dysfunction and increased arterial stiffness (Kishimoto et al., 2019; Zhang et al., 2019). The vasoprotective effects of DPP4 inhibition are mediated through multiple mechanisms, including improved NO bioavailability by upregulation of endothelial NOS, and thus, endothelium-dependent relaxation; reduction of ROS generation, and cyclooxygenase-2 expression; as well as by suppression of inflammatory responses (Zhang et al., 2019; Liu et al., 2020).

Several studies have demonstrated that DPP4 inhibitors ameliorate LVH (Dos Santos et al., 2013; Arruda-Junior et al., 2016; Beraldo et al., 2019; Nakajima et al., 2019; Nam et al., 2019; Okabe et al., 2020), whereas upregulated activity and expression of heart DPP4 is associated with cardiac remodeling and dysfunction (Dos Santos et al., 2013; Arruda-Junior et al., 2016; Beraldo et al., 2019). The antihypertrophic effects of the DPP4 inhibitor teneligliptin have been recently unraveled in an experimental model of Ang II-induced hypertension (Okabe et al., 2020). The authors found that the administration of teneligliptin to C57BL/6 mice suppressed Ang II-induced NADPH oxidase 4 mRNA overexpression, ROS production, and attenuated LVH without affecting blood pressure (Okabe et al., 2020). DPP4 inhibition has also mitigated LV remodeling and dysfunction in other experimental models of hypertension, such as spontaneously hypertensive rats and Dahl salt-sensitive rats (Nakajima et al., 2019; Nam et al., 2019). However, in the

![Diagram](https://example.com/diagram.png)
latter two studies, the gliptin-induced amelioration of cardiac remodeling and dysfunction was accompanied by blood pressure lowering effects.

CONCLUDING REMARKS

The relationship between hypertension, SARS-CoV-2 infection, and tissue injury is complex and multifactorial. Untangling the importance of several pathophysiological mechanisms in COVID-19 severity is still a work in progress, as scientific and clinical knowledge is continually being updated during the current pandemic. Through putative cellular, molecular and functional mechanisms, we provide a conceptual framework on how these biological processes may interact and lead to COVID-19 severity in patients with pre-existing hypertension: the role of the RAS, inflammation, endothelial dysfunction, arterial stiffness, left ventricular hypertrophy and DPP4 are summarized in Figure 1. In brief, patients with hypertension can be more prone to RAS imbalance, which in turn lead to vasoconstriction/inflammation due to unopposed Ang II effect, aggravated by increased DPP4 vascular activity/expression and by chronic low-grade inflammation. This dysregulated response, allied with diminished physiologic cardiovascular reserve induced by hypertension - arterial stiffening, left ventricular hypertrophy and endothelial dysfunction – creates the perfect milieu for both COVID-19 related tissue injury and worsening of cardiac, renal and vascular function.

Targeting these biological processes might attenuate the inflammatory response, reduce tissue injury, and ultimately lead to better outcomes in hypertensive patients with SARS-CoV-2 infection. Also, understanding the pathophysiology of hypertension in cardiovascular hemodynamics and how it might lead to poor outcomes in COVID-19 patients can aid the clinician in making decisions at the bedside. Finally, the role of RAS inhibitors needs to be further investigated, but, to the best of our knowledge, there is no known harmful impact of these medications neither on the risk of infection or disease severity. Noteworthy, preliminary data suggest that these antihypertensive agents may, in fact, confer a protective effect.

AUTHOR CONTRIBUTIONS

All authors conceived, wrote the manuscript and contributed to the article and approved the submitted version.

FUNDING

AG was supported by the São Paulo State Research Foundation (FAPESP) Grants 2016/22140-7 and 2020/05338-3. MB has funding from the Medical Research Council (MR/S01053X/1), British Heart Foundation (PG/16/98/32568), Kidney Research UK (IN001/20170302), and Diabetes UK (17/0005685).

ACKNOWLEDGMENTS

We thank Acaris Benetti for the preparation of Figure 1 and João Carlos Ribeiro da Silva for their helpful comments and discussion on the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2020.599729/full#supplementary-material

REFERENCES


Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Tavares, Bailey and Girardi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC By). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.